Cologuard® recognized as a leading innovation in the state
Exact
Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard was
awarded a Wisconsin Innovation Award (WIA) in the “Healthcare/Health IT”
category at the second annual ceremony held on August 18, 2015 at
Discovery World in Milwaukee, Wisconsin. Cologuard was chosen from more
than 170 entries and 33 finalists to receive one of 10 awards.
“Cologuard is an innovative test for the early detection of colon cancer
that provides patients with an easy-to-use and noninvasive screening
option,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “The
uniqueness of Cologuard is indicative of the creativity, ingenuity and
collaboration taking place throughout Wisconsin. We are honored to be
recognized with this award and remain committed to achieving our mission
of helping eradicate colon cancer through early detection.”
Cologuard is the first and only FDA approved noninvasive stool DNA
screening test for colorectal cancer. It detects the presence of cancer
and precancer by analyzing both DNA and blood in the stool and offers
people an easy-to-use screening test, which they can do in the privacy
of their own home. Unlike other screening options, Cologuard does not
require medication or dietary restrictions or bowel preparation prior to
taking the test. Cologuard is available by prescription only through a
healthcare provider.
Led by a steering committee of business, community and entrepreneurial
leaders, the WIA hopes to encourage an even greater environment of
innovation by bringing together leaders from various business sectors
(e.g. tech, food, healthcare, agriculture, nonprofits, education,
government) and from throughout the state of Wisconsin.
About Cologuard
Cologuard was approved by the FDA in August 2014 and results from Exact
Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal
trial were published in the New England Journal of Medicine in
March 2014. Cologuard is included in the colorectal cancer screening
guidelines of the American Cancer Society and stool DNA is listed in the
screening guidelines of the U.S. Multi-Society Task Force on Colorectal
Cancer.
Cologuard is indicated to screen adults of either sex, 50 years or
older, who are at average risk for colorectal cancer. Cologuard is not
for everyone and is not a replacement for diagnostic colonoscopy or
surveillance colonoscopy in high-risk individuals. False positives and
false negatives do occur. Any positive test result should be followed by
a diagnostic colonoscopy. Following a negative result, patients should
continue participating in a screening program at an interval and with a
method appropriate for the individual patient. Cologuard performance
when used for repeat testing has not been evaluated or established. For
more information about Cologuard, visit www.CologuardTest.com.
Rx Only.
About Exact Sciences
Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company
focused on the early detection and prevention of colorectal cancer. The
company has exclusive intellectual property protecting its noninvasive,
molecular screening technology for the detection of colorectal cancer.
For more information, please visit the company's website at www.exactsciences.com,
follow us on Twitter @ExactSciences
or find us on Facebook.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150819005856/en/
Copyright Business Wire 2015